
Feature|Articles|February 3, 2026
- ONCOLOGY Vol 40, Issue 2
- Volume 40
- Issue 02
‘Stay Curious’ Incoming ASCO President Notes Regarding Successes of Career
Author(s)Ariana Pelosci
Fact checked by: Tim Cortese
Deb Schrag, MD, MPH, will assume the role as ASCO president in 2027, and hopes to continue the work of transcending global, political, and geographic barriers in oncology.
Advertisement
Advertisement
Gastrointestinal (GI) cancer, Deb Schrag, MD, MPH, describes as like playing soccer. It’s a team sport, including not just medical oncologists but radiation oncologists, surgeons, and the entire multidisciplinary team. The incoming American Society of Clinical Oncology (ASCO) president for the 2027-28 term began her career at Columbia Presbyterian during the “triple epidemic” of human immunodeficiency virus (HIV), multidrug-resistant tuberculosis, and cocaine. Training during that period changed her point of view and career trajectory.1
Related to this article

Neoadjuvant eftilagimod alfa, pembrolizumab, and radiotherapy produced an 81.1% 12-month DFS rate in high-risk, resectable soft tissue sarcoma.

“This is the closest we have been to biomarkers replacing ultrasound,” said Amit G. Singal, MD, MS, FAASLD.

ADCs directed towards B7-H3, SEZ, DLL3, and TROP2 appear to be “super exciting,” according to Anne Chiang, MD, PhD.

Rezatapopt monotherapy yielded an ORR of 48% in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer.

Anne Chiang, MD, PhD, discusses DeLLphi-305 and other leaps forward in small cell lung cancer, along with a setback regarding lurbinectedin.

The FDA granted RMAT designation to inzitagene plasmivec for advanced melanoma ahead of a phase 3 trial expected to start in December 2026.

Variation in the mitochondrial genome carries prognostic information about graft-versus-host disease that current clinical risk scores do not capture.
Advertisement
Advertisement

